Related Experiment Video
Updated: Oct 5, 2025
06:07
Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
2.7K
Tumor suppressor CEBPA interacts with and inhibits DNMT3A activity
Xiufei Chen1,2, Wenjie Zhou1,3, Ren-Hua Song4
1Huashan Hospital, Fudan University, and Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), and Molecular and Cell Biology Lab, Institutes of Biomedical Sciences, Shanghai Medical College of Fudan University, Shanghai, China.
Science Advances
|January 26, 2022
Summary
CCAAT/enhancer binding protein α (CEBPA) inhibits DNA methyltransferase 3A (DNMT3A) activity. CEBPA mutations disrupt this interaction, leading to aberrant DNA methylation and increased sensitivity to hypomethylation agents in leukemia.
Area of Science:
- Epigenetics and Gene Regulation
- Cancer Biology
- Molecular Oncology
Background:
- DNA methyltransferases (DNMTs) are crucial for DNA methylation in development and disease.
- Regulation of DNMTs, particularly in cancer, remains incompletely understood.
- CCAAT/enhancer binding protein α (CEBPA) is implicated in various cellular processes.
Purpose of the Study:
- To investigate the interaction between CEBPA and DNA methyltransferase 3A (DNMT3A) isoforms.
- To elucidate the functional consequences of CEBPA mutations on DNMT3A activity and DNA methylation.
- To explore therapeutic strategies for CEBPA-mutated leukemias.
Main Methods:
- Investigated protein-protein interactions between CEBPA and DNMT3A isoforms.
- Assessed the impact of CEBPA on DNMT3A enzymatic activity and DNA binding.
- Analyzed DNA methylation patterns in leukemia cells with CEBPA mutations.
- Evaluated the sensitivity of leukemia cells to hypomethylation agents.
Main Results:
- CEBPA specifically interacts with the DNMT3A isoform, inhibiting its DNA methyltransferase activity.
- Tumor-associated CEBPA mutations disrupt this interaction, causing aberrant DNA methylation, particularly hypermethylation of PRC2 target genes.
- Leukemia cells harboring CEBPA mutations exhibit hypersensitivity to hypomethylation agents.
Conclusions:
- CEBPA acts as a negative regulator of DNMT3A activity, with isoform-specific interactions.
- CEBPA mutations contribute to leukemogenesis through disrupted epigenetic regulation.
- DNA-hypomethylating agents represent a potential therapeutic strategy for CEBPA-mutated leukemia.
More Related Videos
Related Concept Videos
02:23Abnormal Proliferation
4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
01:12Loss of Tumor Suppressor Gene Functions
5.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
5.2K
02:34Inhibition of Cdk Activity
5.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
8.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.3K
02:37DNA Damage can Stall the Cell Cycle
9.4K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.4K
01:23Negative Regulator Molecules
36.4K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.4K